ISA Pharmaceuticals

ISA Pharmaceuticals BV is a clinical-stage immunotherapy company developing rationally designed, fully synthetic immunotherapies to combat cancer and persistent viral infections. The company has built a proprietary immunotherapy platform based on its Synthetic Long Peptide (SLP®) concept and AMPLIVANT® technology. SLP® immunotherapies are designed to optimally exploit and direct the body's own defense mechanisms to fight disease, either as a standalone treatment or in combination with existing therapies.ISA has established its pipeline based on mechanistic insights into how its targeted immunotherapeutics work in patients. Various clinical trials up to Phase II have demonstrated the safety, tolerability, and clinical efficacy (proof-of-concept) of SLP® compounds.